Healthcare

BridgeBio Pharma is evolving from a research-heavy biotech into a commercial rare-disease company, led by fast-rising Attruby revenue. The appeal rests on strong sales growth, specialized science, and multiple pipeline shots that could expand its platform.

Axsome Therapeutics is building a CNS-focused pharmaceutical platform around fast-growing products led by Auvelity and Sunosi. Strong revenue expansion, a broad late-stage pipeline, and improving cash burn make the company increasingly important to watch over the long term.

Baxter supplies essential hospital products, from infusion and renal care to connected-care systems. Its scale, recurring clinical demand, and improving cash flow stand out, while the central question is whether portfolio cleanup can restore margins and strengthen the balance sheet.

Avantor supplies essential materials used in laboratories and biopharma manufacturing, giving it recurring exposure to durable healthcare and research demand. The key attraction is a strong market role in critical workflows, while the central debate is how quickly profitability can recover.

Align Technology is the company behind Invisalign and a growing digital dentistry platform built around scanners and software. The business combines category leadership, strong cash generation, and a very clean balance sheet, while valuation looks far more grounded than in prior years.